Is Trump 2.0 good or bad for healthcare stocks?
- Investing.com
Pro- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Alnylam Pharmaceuticals Inc (ALNY)Alnylam Pharmaceuticals Inc stock price live, this page displays NASDAQ ALNY stock exchange data. View the ALNY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Alnylam Pharmaceuticals Inc real time stock price chart below.
What Is the Alnylam Pharmaceuticals Inc Stock Price Today?
The Alnylam Pharmaceuticals Inc stock price today is 255.89.
What Is the Stock Symbol for Alnylam Pharmaceuticals Inc?
The stock ticker symbol for Alnylam Pharmaceuticals Inc is ALNY.
Is ALNY the Same as $ALNY?
$ALNY is a common way to refer to the Alnylam Pharmaceuticals Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Alnylam Pharmaceuticals Inc Trade On?
Alnylam Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Alnylam Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Alnylam Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Alnylam Pharmaceuticals Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALNY quote. (ISIN: US02043Q1076)
What Is the Alnylam Pharmaceuticals Inc Stock Price Today?
The Alnylam Pharmaceuticals Inc stock price today is 255.89.
What Is the Stock Symbol for Alnylam Pharmaceuticals Inc?
The stock ticker symbol for Alnylam Pharmaceuticals Inc is ALNY.
Is ALNY the Same as $ALNY?
$ALNY is a common way to refer to the Alnylam Pharmaceuticals Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Alnylam Pharmaceuticals Inc Trade On?
Alnylam Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Alnylam Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Alnylam Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Alnylam Pharmaceuticals Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALNY quote. (ISIN: US02043Q1076)
Currency in USD
255.89
-0.37(-0.14%)
Closed
After Hours
253.52-2.37(-0.93%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
252.20
258.12
52 wk Range
141.98
304.39
ALNY Scorecard
Full Analysis
7 analysts have revised their earnings upwards for the upcoming period
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
252.20258.12
52 wk Range
141.98304.39
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
UnlockEV/EBITDA
UnlockBeta
ALNY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
298.77
Upside
+16.76%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Alnylam Pharmaceuticals CFO sells $422,144 in stock
- Investing.com
- Is Trump 2.0 good or bad for healthcare stocks?
- Investing.com
Pro - Alnylam Pharmaceuticals CFO sells $422,144 in stock
- Investing.com
- Alnylam Pharmaceuticals CSO sells $754,945 in stock
- Investing.com
Alnylam Pharmaceuticals Inc Company Profile
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals Inc SWOT Analysis
Analyst Optimism | Price targets range from $205 to $329, reflecting confidence in Alnylam's potential despite challenges in a competitive landscape |
Market Dominance | Explore Alnylam's position in a $5-6B market growing at 65% CAGR, with 80% of patients untreated, presenting substantial expansion opportunities |
Financial Trajectory | Analysts project revenues of $2.2B in 2024, growing to $3.2B in 2025. EPS expected to turn positive, reaching $4.58 in 2025, with profitability on the horizon |
RNAi Breakthrough | Alnylam leads in RNA interference therapeutics, with Amvuttra showing promise for expanding into cardiomyopathy treatment, potentially revolutionizing genetic medicine |
ALNY Full Pro Research
Institutional-Grade Stock Analysis
Understand how ALNY earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Alnylam Pharmaceuticals Inc Earnings Call Summary for Q4/2024
- Global net product revenue up 34% YoY to $420M, led by TTR franchise at $309M
- Positive results from HELIOS-B study; progress in Alzheimer's and Huntington's disease treatments
- Reaffirmed 2024 revenue guidance of $1.575B-$1.65B; preparing for AMVUTTRA launch in 2025
- Aims to double clinical pipeline by end of 2025; exploring business development opportunities
- Royalty revenues up; gross margin improved to 80%; ceased ALN-KHK program for resource reallocation
Last Updated: 10/31/2024, 02:42 PM
Read Full TranscriptCompare ALNY to Peers and Sector
Metrics to compare | ALNY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALNYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −99.3x | −6.9x | −0.6x | |
PEG Ratio | −2.74 | −0.15 | 0.00 | |
Price / Book | 1,020.1x | 1.4x | 2.6x | |
Price / LTM Sales | 15.8x | 7.6x | 3.2x | |
Upside (Analyst Target) | 17.1% | 45.4% | 46.2% | |
Fair Value Upside | Unlock | 8.5% | 7.0% | Unlock |
Analysts' Recommendations
22 Buy
8 Hold
2 Sell
Ratings:
30 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 298.77
(+16.76% Upside)
People Also Watch
FAQ
What Is the Alnylam (ALNY) Stock Price Today?
The Alnylam stock price today is 255.89
What Stock Exchange Does Alnylam Trade On?
Alnylam is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Alnylam?
The stock symbol for Alnylam is "ALNY."
What Is the Alnylam Market Cap?
As of today, Alnylam market cap is 32.96B.
What is Alnylam Earnings Per Share?
The Alnylam EPS is -2.62.
What Is the Next Alnylam Earnings Date?
Alnylam will release its next earnings report on Feb 06, 2025.
From a Technical Analysis Perspective, Is ALNY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.